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Abstract
Objective: Drug named entity recognition (NER) is a critical step
for complex biomedical NLP tasks such as the extraction of pharma-
cogenomic, pharmacodynamic and pharmacokinetic parameters. Large
quantities of high quality training data are almost always a prerequi-
site for employing supervised machine-learning techniques to achieve
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high classification performance. However, the human labour needed
to produce and maintain such resources is a significant limitation. In
this study, we improve the performance of drug NER without relying
exclusively on manual annotations.
Methods: We perform drug NER using either a small gold-standard
corpus (120 abstracts) or no corpus at all. In our approach, we develop
a voting system to combine a number of heterogeneous models, based
on dictionary knowledge, gold-standard corpora and silver annotations,
to enhance performance. To improve recall, we employed genetic pro-
gramming to evolve 11 regular-expression patterns that capture com-
mon drug suffixes and used them as an extra means for recognition.
Materials: Our approach uses a dictionary of drug names, i.e. Drug-
Bank, a small manually annotated corpus, i.e. the pharmacokinetic
corpus, and a part of the UKPMC database, as raw biomedical text.
Gold-standard and silver annotated data are used to train maximum
entropy and multinomial logistic regression classifiers.
Results: Aggregating drug NER methods, based on gold-standard
annotations, dictionary knowledge and patterns, improved the perfor-
mance on models trained on gold-standard annotations, only, achieving
a maximum F-Score of 95%. In addition, combining models trained
on silver annotations, dictionary knowledge and patterns are shown
to achieve comparable performance to models trained exclusively on
gold-standard data. The main reason appears to be the morphological
similarities shared among drug names.
Conclusion: We conclude that gold-standard data are not a hard
requirement for drug NER. Combining heterogeneous models build on
dictionary knowledge can achieve similar or comparable classification
performance with that of the best performing model trained on gold-
standard annotations.
Keywords: named entity annotation sparsity, gold-standard vs. silver-
standard annotations, named entity recogniser aggregation,
genetic-programming-evolved string-similarity patterns, drug named entity
recognition
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1. Introduction
Named entity recognition (NER) is the task of identifying members of var-
ious semantic classes, such as persons, mountains and vehicles in raw text.
In biomedicine, NER is concerned with classes such as proteins, genes, dis-
eases, drugs, organs, DNA sequences, RNA sequences and possibly others [1].
Drugs (as pharmaceutical products) are special types of chemical substances
highly relevant for biomedical research. A simplistic and naive approach to
NER is to directly match textual expressions found in a relevant lexical
repository against raw text. Even though this technique can sometimes
work well, often it suffers from certain limitations. Firstly, its accuracy
heavily depends on the completeness of the dictionary. However, as termi-
nology is constantly evolving, especially in bio-related disciplines, producing
a complete lexical repository is not feasible. Secondly, direct string match-
ing overlooks term ambiguity and variability [2]. On one hand, ambiguous
dictionary entries refer to multiple semantic types (term ambiguity), and
therefore contextual information needs to be considered for disambiguation.
On the other hand, several slightly different tokens may refer to the same se-
mantic type (term variability). Typically, to address these issues, statistical
learning models are deployed for NER.
In such approaches, NER is formalised as a classification task in which an
input expression is either classified as an entity or not. Supervised learning
methods are reported to achieve superior performance than unsupervised
ones, but previously annotated data are essential for training supervised
models [2]. Data annotated by human curators are of high quality and
guarantee best results in exchange for the cost of manual effort. For these
reasons, they are also known as gold-standard data. Due to the cost of man-
ual annotations, corpora for NER are often of limited size and for particular
domains.
Drugs are referred to by their chemical name, generic name or brand
name. Since the chemical name is typically complex and a brand name may
not exclusively identify a drug once the relevant patents expire, a unique
non-proprietary name for the active ingredient is devised for standardised
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scientific reporting and labelling. This generic name is negotiated when
the drug is approved for use, as the nomenclature is tightly regulated by
the World Health Organization (WHO) and local agencies such as the U.S.
Food and Drug Administration (FDA) and the European Medicines Agency.
Several criteria are assessed, such as ensuring the drug action fits the nam-
ing scheme, ease of pronunciation and translation, and differentiation from
other drug names to avoid transcription and reproduction errors during
prescription [3]. Since the naming scheme, assessment criteria and cross-
border synchrony have developed organically over the years, there is neither
a definitive dictionary nor syntax of drug names.
In this study, we investigate methods for achieving high performance in
drug name recognition in cases where either very limited or no gold-standard
training data is available. Our proposed method employs a voting system
able to combine predictions from a number of diverse recognisers. More-
over, genetic programming is used to evolve string-similarity patterns based
on common suffixes of single-token drug names occurring in the DrugBank
database [4]. Subsequently, these patterns are used to compile regular ex-
pressions in order to generalise dictionary entries in an effort to increase
coverage and tagging accuracy.
We compare the performance of our method with several state-of-the-art
NER approaches in recognising manually annotated drug names in the PK
corpus [5]. Where no gold-standard data is available, the proposed method
is shown to achieve competitive performance. In particular, the performance
achieved without gold-standard data is comparable with the performance of
the model aware of gold-standard annotations.
The rest of this paper is organised as follows: section 2. summarises
previous work on drug NER and methods for dealing with data sparsity
in general NER. Section 3. describes the dictionaries and data used in our
experiments, as well as the experimental methodology followed. Sections
4. and 5. present and discuss the experiments and their results. Finally,
section 6. concludes the paper.
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2. Related work
NER is a large, well-studied field of natural language processing (NLP)
[6]. Most publications address it as a supervised task, i.e. the procedure of
training a model on annotated data and then applying it to new text. In the
past, several evaluation challenges have taken place on recognising entities
of the general domain [7–10] as well as scientific domains [2, 11, 12]. In
contrast, research related with Drug NER is limited [13–15]. Very recently,
an evaluation challenge that focussed exclusively on drug name recognition
and drug-drug interactions has taken place [16].
As a result of the collaborative annotation of a large biomedical corpus
project [17], a large-scale biomedical silver standard corpus has been pro-
duced. It contains annotations resulting from the harmonisation of named
entities (NEs) automatically recognised by five different tools, namely, Wha-
tizit [18], Peregrine [19], GeNO [20], MetaMap [21] and I2E [22]. Apart from
names of chemicals and drugs, proteins, genes, diseases and species names
were also tagged by these tools in the 174,999 MEDLINE abstracts com-
prising the corpus. Approximately half a million NE annotations for each
semantic category are contained in the resulting harmonised corpus which
is publicly available. It has been used for the 2 annotation challenges [23].
Dictionaries and ontologies have been used extensively as the basis to
generate patterns and rules for NER. Tsuruoka et al. [24] used logistic re-
gression to learn a string similarity measure from a dictionary, useful for
soft-string matching. Kolarik et al. [25] used lexico-syntactic patterns to ex-
tract terms. Patterns are similar to the ones introduced in [26] and contain
drug names and directly related drug annotation terms found in DrugBank.
Then, these patterns were applied to MEDLINE abstracts, to add annota-
tions of pharmacological effects of drugs. Similar methods have also been ap-
plied for recognising drug-disease interactions [27] and interactions between
compounds and drug-metabolising enzymes [28]. Hettne et al. [29] devel-
oped a rule-based method intended for term filtering and disambiguation.
They identify names of drugs and small molecules by incorporating several
dictionaries such as the UMLS (nlm.nih.gov/research/umls, accessed: 15
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April 2015), MeSH (nlm.nih.gov/mesh, accessed: 15 April 2015), ChEBI
(www.ebi.ac.uk/chebi, accessed: 15 April 2015), DrugBank (drugbank.
ca, accessed: 15 April 2015), KEGG (www.genome.jp/kegg, accessed: 15
April 2015), HMDB (hmdb.ca, accessed: 15 April 2015) and ChemIDplus
(chem.sis.nlm.nih.gov/chemidplus, accessed: 15 April 2015). An earlier
system, EDGAR [30], extracts genes, drugs and relationships between them
using existing ontologies and standard NLP tools such as part-of-speech
taggers and syntactic parsers.
A popular means of dealing with data sparsity in NER is to generate data
semi-automatically or fully automatically. Although, the resulting data is of
lower quality than gold-standard annotations, supervised learners can ben-
efit largely from large volumes of data, since they are based on annotation
statistics. Towards the same ultimate goal, our approach aims to overcome
the restrictions of data sparsity or unavailability in the biomedical domain.
Usami et al. [31] describe an approach for automatically acquiring large
amounts of training data from a lexical database and raw text that relies on
reference information and coordination analysis. Similarly, noisy training
data was obtained by using a few manually annotated abstracts from Fly-
Base (flybase.org, accessed: 15 April 2015) [32, 33]. The approach uses a
bootstrapping method and context-based classifiers to increase the number
of NE mentions in the original noisy training data. Even though they report
high performance, their method requires some minimum curated seed data.
Similarly, Thomas et al. [34] demonstrated the potential of distant learn-
ing in constructing a fully automated relation extraction process. They
produced two distantly labelled corpora for protein-protein & drug-drug in-
teraction extraction, with knowledge found in databases such as IntAct [35]
for genes and DrugBank [4] for drugs.
Active learning is a framework that can be used for reducing the amount
of human effort required to create a training corpus [36, 37]. The most
informative samples are chosen from a big pool of human annotations by a
maximum likelihood model in an iterative and interactive manner. It has
been shown that active learning can often drastically reduce the amount of
training data necessary to achieve the same level of performance compared
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to pure random sampling [38]. A similar approach, accelerated annotation
[39], allows to produce NE annotations for a given corpus at reduced cost.
In contrast to active learning, it aims to annotate all occurrences of the
target NEs, thus minimising the sampling bias. Despite the similarities
between the two frameworks, their goals are different. While active learning
aims to optimise the performance of the corresponding tagger, accelerated
annotation aims to construct an unbiased NE annotated corpus.
3. Methods and data
In this section we present our aggregate classifier for recognising drug names
and the necessary resources.
3.1. Methodology
To classify labels of tokens, we used two classifiers, a maximum entropy
(MaxEnt) model, also known as multinomial logistic regression [40], and a
perceptron classifier [41]. MaxEnt classifiers assume that the best model pa-
rameters are the ones for which each feature’s predicted expectation matches
its empirical expectation and classify instances so that the conditional like-
lihood is maximised. In other words, MaxEnt maximises entropy while con-
forming to the probability distribution drawn by the training set. Perceptron
is a linear classifier that tunes the weights in a network during the training
phase, so as to produce the desired output. The perceptron method is guar-
anteed to locate the combination of weights that solve the problem, if such
a combination exists. We used standard implementations of MaxEnt and
Perceptron, parts of the Apache openNLP project (opennlp.apache.org,
accessed: 15 April 2015).
For both classifiers, we used the same feature set, described below. For
each token, we consider as features:
- tokens: the current and ±2 tokens
- character n-grams: ±2 tokens
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- sentence: a binary feature indicating whether the token appears at
start or end of a sentence
- binary token type features of the current and ±2 tokens, shown in
table 1
- previous map: a binary feature indicating whether the current token
was previously seen as a NE
- prefix and suffix of the current token
- dictionary: a binary feature indicating whether the current token ex-
ists in the dictionary
We attempt to aggregate predictions from dictionaries and NER systems,
under the fundamental hypothesis that the combined output might improve
over the results of single classifiers deployed as standalone. Our aggregate
classifier is compatible with any dictionaries and recognition systems, and
could be applied in other domains and sequence recognition tasks.
We developed a simple voting-system assuming that the predictions of
dictionaries are more reliable than predictions of machine learners. As a
result, the algorithm accepts dictionary predictions as valid if they exist.
This assumption is not true, if a dictionary contains non-drug entities but,
since dictionaries are produced manually, we consider them ideal. Ambigu-
ous NEs might also affect the validity of this assumption. We observed very
little such ambiguities in our dictionary, DrugBank, thus, we accept the
hypothesis to hold in the domain of drug NEs.
Algorithm 1 summarises the voting system. In short, it starts with an
empty list L and iterates over all sentences and tokens of the input text. For
each token, it queries available dictionaries or regular expression patterns
and accepts positive answers as valid. Otherwise, it considers sequentially
each model’s opinion regarding whether the current token is a drug entity
or not. Whenever a model positively recognises a drug-name, we store the
name along with the confidence of the prediction in a map. After consider-
ing the predictions of all models, we store the positive prediction with the
highest confidence, if such a prediction exists, and proceed to the next to-
ken. Predictions of dictionaries or regular expression patterns are assigned
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100% confidence.
After processing all tokens of a sentence, any intersecting or overlapping
spans are removed according to the following rules. For predictions that
cross into each-other, we discard all but the first one. For nested predictions,
only the maximal one is kept. Upon algorithm completion, L should contain
a sequence of maps, each representing the predictions on a single sentence.
At a second experimental stage, we de-constructed the dictionary into 2
distinct models: (a) a model trained on text solely annotated by the dictio-
nary, and (b) an evolved set of string-patterns that attempts to accurately
cover common suffixes of single-token drug names.
For evaluation, we used the standard information retrieval metrics: pre-
cision, recall and F-Score (F1) [42].
3.2. Data
The proposed method requires two types of resources: (a) one or more
comprehensive lexical repositories, such as dictionaries or lexicons. (b) large
amounts of raw text in the domain of interest, which is drugs for the current
study. Supplementally, a small gold-standard corpus may enhance NER
performance if available.
Our method could potentially be applied to recognise any type of biomed-
ical NEs, such as genes and proteins. We choose to focus on identifying drug
names, as this domain has been studied to a much smaller extent. In this
section, we present the resources that we made available to the algorithm
proposed in section 3.1. for experimentation.
3.2.1. DrugBank
As our dictionary, we chose to use DrugBank [4] because it is relatively
up-to-date and provides a mapping between drug-names and common syn-
onyms. DrugBank currently contains more than 6, 700 entries including
1, 447 FDA-approved small molecule drugs, 131 FDA-approved biotech (pro-
tein/peptide) drugs, 85 nutraceuticals and 5, 080 experimental drugs. We
pre-processed the dictionary by normalising all official drug terms and linked
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them to their synonyms in a key-value data-structure. Each key (drug name)
is unique and maps to a single value (a list of synonyms).
3.2.2. The pharmacokinetic corpus
The pharmacokinetic corpus (PK) [5] is manually annotated and consists
of 240 MEDLINE abstracts annotated and labelled on the basis of MESH
terms relevant to pharmacokinetics such as drug names, enzyme names and
pharmacokinetic parameters, e.g. clearance. Half of the corpus is intended
for training (invivo/invitro-train) and half for testing (invivo/invitro-test).
It is freely available at: rweb.compbio.iupui.edu/corpus (Accessed: 15
April 2015). As a pre-processing step, all annotations concerning entities
other than drugs were removed, since this study is concerned with detecting
drug names only.
3.2.3. Raw text
Nowadays, acquiring large amounts of raw text is not a difficult task, even
for very specialised domains. Public electronic repositories of open-access
articles exist for most scientific domains and usually can be queried via
RESTful web services. In biomedicine, for example, UK PubMed Central
(UKPMC, europepmc.org, accessed: 15 April 2015) is an article database
which extends the functionality of the original PubMed Central (ncbi.nlm.
nih.gov/pmc, accessed: 15 April 2015) repository. For the purposes of
this study, we used a small subset of the entire UKPMC database which
includes more than two million papers. The sample we used was created
by Miha˘ila˘ and Navarro [43], totalling 360 pharmacology and cell-biology
related articles. As a pre-processing step, the corpus was sentence-split and
tokenised. Part-of-speech tagging was omitted from the process since we did
not plan to use the part-of-speech tags as features during training.
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4. Experimental results
The first set of experiments, in section 4.1., considered the entire set of gold-
standard annotations. In the second set, we assess the importance of silver
data, i.e. data annotated by recognising dictionary entries on raw text. We
evaluate the performance of our classifier trained on silver data only, and
we also combine gold and silver data to measure whether the combination
can boost performance. In succession, we investigate how we can produce
string similarity patterns based on dictionary knowledge to further increase
recall. Finally, we investigate how the proposed aggregate classifier performs
in absence of gold-standard annotations.
4.1. Baselines
Firstly, we tested how the dictionary performs as a single recogniser, includ-
ing or excluding synonyms. Secondly, we trained two NE recognisers, namely
a MaxEnt and a perceptron classifier, on half the PK corpus (invivo/invitro-
train) and tested them on the other half (invivo/invitro-test). Finally, we
used our prediction aggregation algorithm to combine predictions originat-
ing from the dictionary, with predictions originating from the classifiers.
Table 2 presents the results from our baseline experiments. It is worth
noting that the pure dictionary-based approach is not 100% precise as our
voting system assumes. Careful error analysis revealed that there are at
least two entities, i.e. “nitric oxide” and “tranylcypromine” that have not
been tagged in the gold-standard corpus. Consequently, the evaluator marks
them as false-positives while, in fact, they are perfectly correct predictions.
Another interesting observation is that including synonyms causes precision
to degrade. Synonyms in DrugBank often include acronyms, which have
not been tagged appropriately in the test corpus. As before, the evaluator
classifies them as false-positives.
In general, we can see that both the dictionary and the classifiers ex-
hibit very high precision and good recall, whereas combining the two has
a minimal positive effect on overall performance. The perceptron classifier,
despite training significantly faster, consistently showed inferior performance
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in comparison with MaxEnt.
Unfortunately, no other experimental results on the exact data that we
experimented with have been published. However, to put our results into
perspective, we can consider the results of a recent evaluation challenge,
SemEval-2013 Task 9: DDIExtraction [16]. Its first subtask was concerned
with recognising and classifying drug names. Several participating systems
aimed at recognising generic and branded drug names, among other entities.
Table 3 show the exact-matching precision, recall and F-Score achieved by
the best performing systems in terms of F-Score in the categories of generic
and branded drug names. The DDIExtraction 2013 task was evaluated on
the DDI corpus, which consists of 784 DrugBank texts and 233 MEDLINE
abstracts and was manually annotated [44]. Although the data used in this
work are not identical to the DDI corpus, the results in table 3 can be used
as indirect baselines. It can be observed that the our baseline results in table
2 are comparable if not slightly better than the best performing systems the
DDIExtraction2013 task, despite the fact that we trained on significantly
smaller and possibly lower-quality data.
Our baseline experiments show that, despite acquiring state-of-the-art
precision, there is still space for improvement with regards to recall. High
precision indicates that the model extracts some very informative features
while training, whereas not so high recall essentially reflects lack of enough
training data. Ideally, we would need more gold-standard annotations, how-
ever, as discussed previously, this is not always feasible.
4.2. Combining heterogeneous models
Attempting to improve recall, we trained separate models purely on silver
data, i.e. data annotated by direct string-matching dictionary entries. An-
notation coverage ultimately depends on the quality of the dictionary, its
coverage and how up-to-date it is. DrugBank is a good candidate for this
task, as it is a comprehensive dictionary of drugs and also freely available.
The 360 full papers mentioned in section 3.2.3. were annotated and parti-
tioned into 30 collections, each one containing 12 items. This was done in an
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effort to incrementally check whether the addition of silver annotations has
any positive or negative effects on classifier’s performance. We found that
we had to include all 30 partitions in order to witness some improvement.
Table 6 summarises the results of our experiments. The MaxEnt classifier
trained on silver annotation data achieves marginally higher precision and
significantly lower recall than the same classifier trained on gold-standard
data. This is expected, since the silver annotations reflect the contents of
the dictionary, only. Trained on a mixture of gold and silver data, the
MaxEnt classifier achieves 0.5% lower precision and 0.3% higher recall than
its equivalent trained on gold-standard data.
Including the dictionary boosts the recall of the MaxEnt classifier trained
on a mixture of gold-standard and silver annotation data by 1.3% in com-
parison with its baseline equivalent. The last 2 rows of Table 4 show that all
statistics were slightly boosted just by utilising these extra, easy to produce
silver annotations.
In all our experiments so far, the best achieved recall is 89.7%, far less
than precision, thus, we focus on improving it. Careful examination of false-
negatives reveals that most of them are either acronyms (e.g. HMR1766),
long chemical descriptions (e.g. 5beta-cholestane-3alpha, 7alpha, 12alpha-
triol) or terms whose lexical morphology is particularly different than the
usual morphology of drugs (e.g. grapefruit juice). We attempted to capture
acronyms by employing a state-of-the-art acronym disambiguator, AcroMine
[45], however it did not disambiguate any of the acronyms in question, listed
below:
- ANF
- E3174
- PO4
- RPR 106541
- HMR1766
- MDZ 4-OH
- MDZ 1’-OH
Under data sparsity, it is crucial to extract maximum utility from our
training set, which necessitates incorporation of features with low occurrence
frequency. The MaxEnt and perceptron models we employ do not consider
the uncertainty introduced by low frequency training data, hence a frequency
threshold value is introduced to control the compromise between precision
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and recall. For our experiments we set this threshold at 5, as lower values
detrimentally affected precision. As discussed, a number of false-negatives
were missed due to their morphology which is different than the usual mor-
phology of drugs. These two facts, suggest that probably some informative
features did not qualify due to the frequency threshold value. It should be
noted that, in contrast to the MaxEnt classifier, which is probabilistic, the
perceptron classifier is not affected by the frequency threshold. The per-
ceptron is essentially a neural network, thus it does not gather probabilities
and therefore performs best when no frequency threshold is applied.
Beyond the scope of this paper, there are more sophisticated methods to
select important features or tune feature weights to address data sparsity.
In general, two smoothing approaches [46] are applied: linear interpolation
[47] and back-off models [48–51]. Data sparsity can also be addressed by
feature relaxation, based on hierarchical features [52]. A more sophisticated
approach to feature weighting would be to employ Dirichlet regression [53–
55] rather than MaxEnt. Dirichlet regression considers frequencies directly
as the dependent variable, rather than probabilities as in multinomial logistic
regression. The sum of frequencies for a particular feature represents its
“precision”. It should be noted that for high frequency data Dirichlet and
multinomial logistic regression models behave similarly.
4.3. Evolving string-similarity patterns
In this section we aim to improve recall by learning string similarity pat-
terns based on dictionary knowledge. Exploring ways to restore the predic-
tive power the model could have if more training data were available, we
develop a mechanism to deal with these easy, yet elusive false-negative cases
discussed in the previous section. We attempt to genetically evolve string
patterns that can then be used as regular expressions to capture drug names
that are not present in the dictionary. We followed a three-step process de-
scribed below: genetic programming, filtering and pattern augmentation.
Following the work of Tsuruoka et al. [24], we also use a form of re-
gression in order to learn common string patterns of drug names. More
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specifically, we used genetic programming, also known as symbolic regres-
sion, a technique which allows the evolution of programs at the symbolic
level [56]. Genetic programming is used in this task as a global optimi-
sation algorithm.
The pseudo-random sampling inherent in genetic programming means
that no hard guarantees about the final outcome can be made. However, the
randomness also enables good coverage of the fitness landscape and therefore
avoids falling into local optima, which is essential to solve our problem.
Furthermore, the self-driven nature of evolution is robust as it makes little
to no assumptions about the fitness landscape, thus mitigating bias during
the learning stage, which enables it to produce meaningful solutions where
other global optimisation algorithms can falter [56]. Learning by means of
evolution is a good fit for our use-case as it allows finding decent solutions
with minimal prior knowledge.
Genetic programs assemble variable length program structures from the
basic units, i.e. functions and terminals. The assembly occurs at the begin-
ning of a run, when the populations is initialised. In succession, programs
are transformed using genetic operators, such as crossover, mutation and re-
production. The algorithm evolves a population of programs by determining
which individuals to improve based on their fitness, which is in turn assessed
by the fitness-function.
In our implementation, genetic programs were represented as trees that
were traversed in a depth-first manner. A fitness function, a function set and
a terminal set are required for developing a genetic algorithm. Terminals
provide the values that can be assigned to the tree leaves, while functions
perform operations on either terminals or on the output of other functions.
Typically, the function set of a genetic algorithm that deals with numerical
calculations contains the four basic arithmetic operations (+ - * /), while the
terminal set contains one-digit non-negative integers, [0-9]. In the current
case, the function and terminal sets have to deal with strings. The terminal
set contains all latin lowercase letters, [a-z], plus several other characters
needed for building meaningful regular expressions, i.e. | \* + ? ( ) [ ]. The
function set contains several string-manipulating functions, e.g. split, join
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and concatenate.
We employed two genetic operators, crossover and mutation. As illus-
trated in figure 2, tree-based crossover generates new individuals by swap-
ping subtrees of existing individuals. The population percentage applicable
to crossover was set to 35%. Mutation typically operates on one individual.
As shown in figure 3, a point in the tree under mutation is chosen and the
corresponding subtree is replaced with a new randomly generated subtree.
This new subtree is created in the same way, and is subject to the same lim-
itations as the original trees in the initial population. As a matter of future
work, more genetic operators can be employed. Although we attempt to
employ the simplest genetic operators possible, evolving similarity patterns
by genetic programming is the most demanding part of this work, in terms
of computational complexity.
Each “organism” in the genetic population is a small program. When
executed, the program produces a string that is assigned a score accord-
ing to the fitness function. For this purpose, all the single-word terms
were extracted from DrugBank and were used as “test-data” within the
fitness function, which returns the proportion of matches as a measure
of fitness. In case the string produced is not a valid regular expression,
the candidate receives negative score and will most likely be disregarded
in the next generation. For instance, a candidate that matches 50/6,700
terms in DrugBank is obviously fitter than one that matches only 10/6,700
terms, which in turn, is fitter than one whose string does not compile as
a regular expression. However, genetic programming did not achieve any-
thing less than 100% error when attempting to match entire tokens, and
so we limited the testing scope to the last 4, 5 or 6 characters of each to-
ken. This decision was made after observing that word-endings tend to
be more similar than word-beginnings in drug names, mainly for confor-
mance with the WHO’s international non-proprietary name stem group-
ing (who.int/medicines/services/inn/stembook/en, accessed: 15 April
2015). This had a major positive effect on the population in most executions.
After 200 experiments with 80 generations per experiment and 10, 000 in-
dividuals per generation, the 30 best-evolved individuals were selected. Each
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individual is a function that builds a string that represents a potentially
common suffix, in the form of a regular expression pattern. The pattern
produced by the best individual matched 7.3% of the terms in the test-set
(130 terms). It should be noted that the evolutionary process evaluates can-
didates using a list of singletons and not actual sentences. As a consequence,
these patterns will most likely introduce false-positives if applied directly on
real text, thus, decreasing precision.
In succession, we aim to keep the top performing patterns only, i.e. the
least likely to introduce false-positives. This filtering can be done either
manually or algorithmically. Since the number of patterns is small, the
cost of manual checking by a domain expert is limited. Non-experts could
also accomplish this task. Instead, we chose to increase the applicability of
our approach, we selected the best patterns automatically. We calculated
all possible combinations of sets of 5 string patterns and performed an ex-
tensive evaluation process where each combination was evaluated only for
false-positives on 10 randomly selected paragraphs from the original training
set (PK corpus). We selected 5 sets of patterns (25 patterns) which intro-
duced the least false-positives. These 25 patterns were reduced to 11 after
removing duplicates and those that would clearly introduce false-positives.
For example, the pattern “m?ine” was removed because it would recognise
“fluvoxamine” correctly, but it would also incorrectly recognise as drugs
words such as “examine”, “define”, “jasmine” and “cosine”. Table 5 shows
the 11 best performing patterns, accompanied with the number of matches
and an example for each one, while figure 1 shows the tree that corresponds
to the best performing pattern.
Finally, in the pattern augmentation step, we augmented these 11
patterns by wrapping them as follows:
\b (\d?\,?\d’?\-?)?\w+ <pattern>+ \b
The string “\b” at the start and end of the pattern, make it applica-
ble to whole words only. The string “(\d?\,?\d’?\-?)?\w+” specifies op-
tional triggers, i.e. digits, commas and dashes, mainly for matching hy-
droxylated compounds. For example if a pattern applies to “midazolam”,
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it also matches “4-hydroxymidazolam”, “4,5-hydroxymidazolam” and “4,5’-
hydroxymidazolam”. It is common knowledge in biochemistry that all or-
ganic compounds go through oxidative degradation when they come in con-
tact with air. Hydroxylation is the first step in that process and con-
verts lipophilic compounds into water-soluble (hydrophilic) products that
are more readily excreted. We observe many mentions of such compounds
in pharmacology papers, and therefore we attempt to capture them with
this simple regular expression. The pattern augmentation rule, was chosen
manually, introducing a minimal human interaction in this last step.
The genetic programming paradigm parallels nature in that it is a never-
ending process. In practise however, and particularly when evolving code,
arbitrary complexity is rarely desired because it is very easy for the model to
over-fit or start deviating substantially from a good solution approximation.
We adopt two simple and widely used termination criteria to address this.
We stopped the evolution process (a) after a number of iterations (genera-
tions) and (b) by setting a maximum allowed tree depth (10). The patterns
were evolved assuming that each will span a single word term.
4.4. Evaluation of evolved patterns
We evaluated the best augmented patterns (table 5) as a separate classifi-
cation model. During aggregations, similarly to the dictionary predictions,
positive predictions of the pattern model are assigned a probability of 100%.
Table 6 shows evaluation results. As a first observation, classifier ensembles
trained both on gold-standard and silver annotation data do not perform
better than classifier ensembles trained on gold-standard data, only. Com-
bining the dictionary and the pattern model compensates for the lack of
a lower-quality model both for the MaxEnt and the perceptron classifier.
Comparing tables 2, 4 and 6 demonstrates how we gradually moved from the
recall range 84%-88% to 89%-93%, while keeping precision above 96%-97%.
In fact, there are some verified annotation inconsistencies in the test corpus
responsible for a minor decrease in precision. More specifically, some terms,
such as 3-hydroxyquinidine, cycloguanil and 4-hydroxyomeprazole, have not
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been appropriately tagged as drugs.
4.5. Ignoring gold-standard data
In our experiments so far, we assumed that at least some gold-standard data
is available for training. However this might not always be the case. In this
section, we are concerned with the question: “How much worse would results
be, in the absence of a gold-standard training set?” This is an important
question because, as discussed earlier, gold-standard annotations are time
consuming and costly. Ignoring expensive annotations, we experiment with
classifiers trained on the easy-to-produce automatically generated annota-
tions, the dictionary and the pattern model. The same gold-standard corpus
was used for testing and each incremental improvement was also tested for
statistical significance against the previous one using chi-square test, with
and without Yate’s correction. In all cases, improvements were found to be
statistically significant with p-values ranging from 10−4 to 4 × 10−4. The
results obtained are shown in Table 7.
Comparing these results with the ones from our baseline experiments,
presented in Table 2, shows that the MaxEnt classifier trained solely on sil-
ver annotation data, combined with the dictionary and the pattern model,
achieves similar performance to the MaxEnt classifier trained on gold-standard
data. This result is encouraging, since it suggests that access to gold-
standard data is not necessarily a prerequisite for high performance drug-
NER.
5. Discussion
Using a lexical database to annotate NEs in raw text is not a new concept.
In fact, since lexical databases are manually annotated, annotating sentences
for NEs from scratch certainly contains some level of effort duplication. We
attempted to automate the annotation process by utilising such resources.
Unfortunately, our results show that using a dictionary as a direct annotator
of drug names achieves top precision but limited recall. Classifiers trained on
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gold-standard annotations achieved comparable precision but much higher
recall.
For these reasons, we attempted to experiment with methods to pre-
process DrugBank before using it as an annotator. To increase recall we
generalised dictionary entries into regular expression patterns. We were
expecting that the patterns would be able to capture drug names that were
not listed in the dictionary but share common morphological characteristics,
such as suffixes or prefixes, with some dictionary entries.
Obtaining such patterns automatically and accurately is hard and, thus,
our list of patterns is neither perfect nor complete. Perhaps a pharmacolo-
gist cooperating with a regular-expression expert would find higher quality
patterns, i.e. patterns that generalise better. However, we prefer to explore
the extent to which automatic methods can address this task adequately. In
the future it would be very interesting to compare our automated method
with expert-driven regular expressions, together with incorporation of rules
derived from existing WHO and FDA drug nomenclature processes.
Throughout our experiments, we relied heavily on the proposed algo-
rithm for aggregating predictions, which is also not perfect. It is based
on assumptions that may not hold in a different context. Moreover, the
algorithm always favours predictions of the knowledge-based models (dic-
tionaries and regular expressions) against learning models, accepting the in-
consistencies of knowledge-based models as valid. The manually constructed
dictionary was of major importance for this study, as it was used in a num-
ber of ways. It was the basis to extract synonyms, common word-ending
patterns, and was also seen as a direct annotator for an entire corpus. Vot-
ing systems similar to the proposed prediction aggregation algorithm are
becoming increasingly popular mainly to boost performance but also for the
overall stability of the resulting classifier [57–61].
It is also noteworthy that both sets of gold-standard data, for training
and testing, are of roughly the same size. Contrasting this with other sim-
ilar NER experiments, we find that the testing-set is usually a lot smaller
than the training-set regardless of the evaluation scheme (holdout or cross-
validation). This is due to the fact that the problem of data-sparsity is
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pervasive across the entire text mining and NLP discipline (with regards to
probabilistic training). In practice, this means that there is rarely enough
training data, thus splitting it in two equally sized pieces will most likely
not lead to satisfying statistics. We decided to leave the data as is, in order
for the experiments to be as easily reproducible as possible.
Our results demonstrate that, even though availability of gold-standard
data is certainly helpful, it is not a strict requirement with regards to drug
NER. Drugs often share several morphological characteristics, which reduces
the contextual information that is needed in order to make informed predic-
tions. Nonetheless, it remains to be investigated whether our combination
of heterogeneous models will achieve high performance when tested against
larger corpora.
6. Conclusions and future work
This study mainly focused on achieving high performance drug NER with
very limited or no manual annotations. We achieved this by merging predic-
tions from several heterogeneous models including models trained on gold-
standard data, models trained on silver annotation data, DrugBank and,
finally, evolved regular expression patterns. We have shown that state-of-
the-art performance in drug NER is within reach, even in the presence of
data sparsity.
Our experiments also show that combining heterogeneous models can
achieve similar or comparable classification performance with that of our
best performing model trained on gold-standard annotations. We have
shown that in the pharmacology domain, static knowledge resources such
as dictionaries actually contain more information than is immediately ap-
parent, and therefore can be utilised in other, non-static contexts (i.e. to
devise high-precision regular expression patterns). Including synonyms in
the dictionary or disambiguating acronyms did not improve results in this
study mainly due to certain design decisions that surround the PK corpus.
More specifically, none of the tagged acronyms were identified by AcroMine,
whereas most of the identified synonyms have simply not been tagged ap-
21
propriately in the test-set. Generally speaking however, we would expect a
significant performance boost from applying these methods.
We plan to extend this work in the future. First of all, we plan to take
advantage of all the annotations in the PK corpus. Being able to recognise
both drugs and drug-targets is essential for the task of identifying relation-
ships and interactions between them. We are also very interested to see if we
can improve on, or find more accurate regular expression patterns in order
to enrich our “safety net” model. Moreover, choosing a drug name is a very
long and costly process, and therefore generating good quality candidates
automatically would be very useful. Finally, we would like to extend our
prediction-aggregation algorithm so as to assign probabilities to predictions
of the knowledge-based models (dictionaries and regular expressions).
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Algorithms
Algorithm 1 Aggregation of predictions
1: List L →[ ]
2: for all Sentence s ∈ Text do
3: Map M → {:prediction :confidence}
4: for all Tokens t ∈ s do
5: if ∃ dictionary then
6: if dictionary.predict(t) → POSITIVE then
7: PUT M {prediction 1.0}
8: else
9: for all Model m ∈ Models do
10: if m.predict(t) → POSITIVE then
11: STORE {prediction confidence}
12: end if
13: end for
14: PUT M {prediction max-confidence}
15: end if
16: end if
17: end for
18: DROP overlapping/intersecting spans*
19: ADD L M
20: end for
21: return L
* Rules for dropping spans:
- Identical/Intersecting : first span is kept
- Contained : Contained spans are dropped
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Figure 1: The best-evolved “organism”
Figure 2: Example of one-point crossover between parents of different sizes
and shapes. Image source: [62]
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Figure 3: Example of subtree mutation. Image source: [62]
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Tables
token type features
initial capital letter contains hyphen
all lowercase letters contains slash
all letters contains period
all digits contains uppercase
contains digit contains letters
Table 1: Binary token type features
classifier P R F1
Dictionary 99.7% 78.5% 87.8%
Dictionary + synonyms 93.4% 78.9% 85.6%
MaxEnt(gold) 98.3% 84.5% 91.0%
Perceptron(gold) 97.5% 72.0% 82.8%
MaxEnt(gold) + Dictionary 99.1% 88.4% 93.4%
Perceptron(gold) + Dictionary 97.6% 84.3% 90.4%
Table 2: Results of baseline classifiers trained on gold-standard data (P:
precision, R: recall, F1: F-Score)
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category general drug names branded drug names
system NLM LHC [16] UTurku [15]
team National Library of Medicine University of Turku
approach dictionary-based SVM classifier (TEES)
precision 72.5% 94.5%
recall 91.7% 88.1%
F-Score 81.0% 91.2%
Table 3: Results of the best performing systems (in terms of exact-matching
F-Score) in general and branded drug name recognition in the DDIExtrac-
tion 2013 task [16].
classifier P R F1
MaxEnt (silver) 98.7% 47.1% 63.7%
MaxEnt (silver) + dictionary 99.2% 78.5% 87.6%
Perceptron (silver) 98.3% 76.9% 86.3%
Perceptron (silver) + dictionary 99.3% 78.5% 87.7%
MaxEnt (gold + silver) 97.8% 84.8% 91.0%
MaxEnt (gold + silver) + dictionary 98.6% 89.7% 93.9%
Perceptron (gold + silver) 97.2% 79.1% 87.2%
Perceptron (gold + silver) + dictionary 98.0% 85.1% 91.1%
Table 4: Results of classifiers trained on gold-standard and silver annotation
data (P: precision, R: recall, F1: F-Score)
evolved patterns matches example
a(z|st|p)ine? 130 nevirapine
(i|u)dine? 72 lepirudin
azo(l|n)e? 62 fluconazole
tamine? 44 dobutamine
zepam 17 bromazepam
zolam 13 haloxazolam
(y|u)lline? 12 enprofylline
artane? 11 eprosartan
retine? 10 hesperetin
navir 9 saquinavir
ocaine 9 benzocaine
Table 5: Evolved patterns
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classifier P R F1
MaxEnt (gold) + dictionary + patterns 97.3% 93.0% 95.1%
MaxEnt (gold + silver) + dictionary + patterns 97.3% 93.0% 95.1%
Perceptron (gold) + dictionary + patterns 95.8% 88.9% 92.3%
Perceptron (gold + silver) + dictionary + patterns 96.0% 88.8% 92.3%
Table 6: Evaluation results of ensembles that contain the pattern classifier
(P: precision, R: recall, F1: F-Score)
classifier P R F1
MaxEnt (silver) + dictionary + patterns 97.4% 85.4% 91.0%
Perceptron (silver) + dictionary + patterns 97.3% 85.1% 90.8%
Table 7: Results of classifiers that did not use gold-standard data (P: preci-
sion, R: recall, F1: F-Score)
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